Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency

G. M. Turino, A. F. Barker, M. L. Brantly, A. B. Cohen, R. P. Connelly, Ronald Crystal, E. Eden, M. D. Schluchter, J. K. Stoller

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

This report describes the clinical characteristics of a group of 59 individuals with the PI* SZ phenotype and α1-antitrypsin (α1-AT) deficiency, identified during recruitment of a registry for subjects with severe α1-antitrypsin deficiency. Currently, 1,129 individuals with levels of α1-AT of 11 μM or below have been enrolled in this registry. Individuals with the SZ phenotype whose α1-AT levels are at or below 11 μM will be followed in the registry; those whose levels exceeded 11 μM had baseline studies and are included in this report. Baseline pulmonary function tests included spirometry before and after an inhaled bronchodilator, diffusing capacity for carbon monoxide (DL(CO)), and chest roentgenograms. Among nonsmokers, subjects with the SZ phenotype demonstrated airflow obstruction less frequently than those with with the ZZ phenotype. Among ex- and current smokers, the frequency and severity of airflow obstruction was similar between SZ and ZZ subjects. Individuals with the SZ phenotype reported respiratory symptoms less frequently than did ZZ subjects. Overall, airflow obstruction was less common and milder among PI*SZ than PI*ZZ subjects. Cigarette smoking correlated more strongly with airflow obstruction among PI*SZ than PI*ZZ subjects. These observations indicate that in smokers, the PI*SZ phenotype confers a significant risk of the development of chronic obstructive pulmonary disease (COPD). Of itself, except in rare instances in nonsmoking individuals, the PI*SZ phenotype may confer little or no added risk of developing COPD.

Original languageEnglish
Pages (from-to)1718-1725
Number of pages8
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume154
Issue number6
Publication statusPublished - 1 Dec 1996
Externally publishedYes

Fingerprint

Phenotype
Registries
Carbon Monoxide
Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Spirometry
Respiratory Function Tests
1,5-bis(3,4-dimethoxyphenyl)tetrahydropyran
Thorax
Smoking

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Turino, G. M., Barker, A. F., Brantly, M. L., Cohen, A. B., Connelly, R. P., Crystal, R., ... Stoller, J. K. (1996). Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency. American Journal of Respiratory and Critical Care Medicine, 154(6), 1718-1725.

Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency. / Turino, G. M.; Barker, A. F.; Brantly, M. L.; Cohen, A. B.; Connelly, R. P.; Crystal, Ronald; Eden, E.; Schluchter, M. D.; Stoller, J. K.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 154, No. 6, 01.12.1996, p. 1718-1725.

Research output: Contribution to journalArticle

Turino, GM, Barker, AF, Brantly, ML, Cohen, AB, Connelly, RP, Crystal, R, Eden, E, Schluchter, MD & Stoller, JK 1996, 'Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency', American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 6, pp. 1718-1725.
Turino, G. M. ; Barker, A. F. ; Brantly, M. L. ; Cohen, A. B. ; Connelly, R. P. ; Crystal, Ronald ; Eden, E. ; Schluchter, M. D. ; Stoller, J. K. / Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency. In: American Journal of Respiratory and Critical Care Medicine. 1996 ; Vol. 154, No. 6. pp. 1718-1725.
@article{9953be28c93b49ada5ee8244f28b0791,
title = "Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency",
abstract = "This report describes the clinical characteristics of a group of 59 individuals with the PI* SZ phenotype and α1-antitrypsin (α1-AT) deficiency, identified during recruitment of a registry for subjects with severe α1-antitrypsin deficiency. Currently, 1,129 individuals with levels of α1-AT of 11 μM or below have been enrolled in this registry. Individuals with the SZ phenotype whose α1-AT levels are at or below 11 μM will be followed in the registry; those whose levels exceeded 11 μM had baseline studies and are included in this report. Baseline pulmonary function tests included spirometry before and after an inhaled bronchodilator, diffusing capacity for carbon monoxide (DL(CO)), and chest roentgenograms. Among nonsmokers, subjects with the SZ phenotype demonstrated airflow obstruction less frequently than those with with the ZZ phenotype. Among ex- and current smokers, the frequency and severity of airflow obstruction was similar between SZ and ZZ subjects. Individuals with the SZ phenotype reported respiratory symptoms less frequently than did ZZ subjects. Overall, airflow obstruction was less common and milder among PI*SZ than PI*ZZ subjects. Cigarette smoking correlated more strongly with airflow obstruction among PI*SZ than PI*ZZ subjects. These observations indicate that in smokers, the PI*SZ phenotype confers a significant risk of the development of chronic obstructive pulmonary disease (COPD). Of itself, except in rare instances in nonsmoking individuals, the PI*SZ phenotype may confer little or no added risk of developing COPD.",
author = "Turino, {G. M.} and Barker, {A. F.} and Brantly, {M. L.} and Cohen, {A. B.} and Connelly, {R. P.} and Ronald Crystal and E. Eden and Schluchter, {M. D.} and Stoller, {J. K.}",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "154",
pages = "1718--1725",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "6",

}

TY - JOUR

T1 - Clinical features of individuals with PI*SZ phenotype of α1- antitrypsin deficiency

AU - Turino, G. M.

AU - Barker, A. F.

AU - Brantly, M. L.

AU - Cohen, A. B.

AU - Connelly, R. P.

AU - Crystal, Ronald

AU - Eden, E.

AU - Schluchter, M. D.

AU - Stoller, J. K.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - This report describes the clinical characteristics of a group of 59 individuals with the PI* SZ phenotype and α1-antitrypsin (α1-AT) deficiency, identified during recruitment of a registry for subjects with severe α1-antitrypsin deficiency. Currently, 1,129 individuals with levels of α1-AT of 11 μM or below have been enrolled in this registry. Individuals with the SZ phenotype whose α1-AT levels are at or below 11 μM will be followed in the registry; those whose levels exceeded 11 μM had baseline studies and are included in this report. Baseline pulmonary function tests included spirometry before and after an inhaled bronchodilator, diffusing capacity for carbon monoxide (DL(CO)), and chest roentgenograms. Among nonsmokers, subjects with the SZ phenotype demonstrated airflow obstruction less frequently than those with with the ZZ phenotype. Among ex- and current smokers, the frequency and severity of airflow obstruction was similar between SZ and ZZ subjects. Individuals with the SZ phenotype reported respiratory symptoms less frequently than did ZZ subjects. Overall, airflow obstruction was less common and milder among PI*SZ than PI*ZZ subjects. Cigarette smoking correlated more strongly with airflow obstruction among PI*SZ than PI*ZZ subjects. These observations indicate that in smokers, the PI*SZ phenotype confers a significant risk of the development of chronic obstructive pulmonary disease (COPD). Of itself, except in rare instances in nonsmoking individuals, the PI*SZ phenotype may confer little or no added risk of developing COPD.

AB - This report describes the clinical characteristics of a group of 59 individuals with the PI* SZ phenotype and α1-antitrypsin (α1-AT) deficiency, identified during recruitment of a registry for subjects with severe α1-antitrypsin deficiency. Currently, 1,129 individuals with levels of α1-AT of 11 μM or below have been enrolled in this registry. Individuals with the SZ phenotype whose α1-AT levels are at or below 11 μM will be followed in the registry; those whose levels exceeded 11 μM had baseline studies and are included in this report. Baseline pulmonary function tests included spirometry before and after an inhaled bronchodilator, diffusing capacity for carbon monoxide (DL(CO)), and chest roentgenograms. Among nonsmokers, subjects with the SZ phenotype demonstrated airflow obstruction less frequently than those with with the ZZ phenotype. Among ex- and current smokers, the frequency and severity of airflow obstruction was similar between SZ and ZZ subjects. Individuals with the SZ phenotype reported respiratory symptoms less frequently than did ZZ subjects. Overall, airflow obstruction was less common and milder among PI*SZ than PI*ZZ subjects. Cigarette smoking correlated more strongly with airflow obstruction among PI*SZ than PI*ZZ subjects. These observations indicate that in smokers, the PI*SZ phenotype confers a significant risk of the development of chronic obstructive pulmonary disease (COPD). Of itself, except in rare instances in nonsmoking individuals, the PI*SZ phenotype may confer little or no added risk of developing COPD.

UR - http://www.scopus.com/inward/record.url?scp=0030446288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030446288&partnerID=8YFLogxK

M3 - Article

C2 - 8970361

AN - SCOPUS:0030446288

VL - 154

SP - 1718

EP - 1725

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 6

ER -